Found: 14
Select item for more details and to access through your institution.
Guselkumab 在接受 100 周治疗的银屑病患者中的安全性.
- Published in:
- British Journal of Dermatology, 2019, v. 180, n. 5, p. e168, doi. 10.1111/bjd.17807
- By:
- Publication type:
- Article
Safety of guselkumab in patients with psoriasis treated through 100 weeks.
- Published in:
- British Journal of Dermatology, 2019, v. 180, n. 5, p. e156, doi. 10.1111/bjd.17795
- By:
- Publication type:
- Article
Safety of guselkumab in patients with moderate‐to‐severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.
- Published in:
- British Journal of Dermatology, 2019, v. 180, n. 5, p. 1039, doi. 10.1111/bjd.17454
- By:
- Publication type:
- Article
Guselkumab 对使用优特克单抗疗效不佳的银屑病患者的有效性和安全性:随机、双盲 III 期 NAVIGATE 试验结果
- Published in:
- British Journal of Dermatology, 2018, v. 178, n. 1, p. e88, doi. 10.1111/bjd.16181
- By:
- Publication type:
- Article
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial.
- Published in:
- British Journal of Dermatology, 2018, v. 178, n. 1, p. e69, doi. 10.1111/bjd.16175
- By:
- Publication type:
- Article
Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
- Published in:
- British Journal of Dermatology, 2018, v. 178, n. 1, p. 132, doi. 10.1111/bjd.16008
- By:
- Publication type:
- Article
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase III NAVIGATE trial.
- Published in:
- British Journal of Dermatology, 2018, v. 178, n. 1, p. 114, doi. 10.1111/bjd.15750
- By:
- Publication type:
- Article
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.
- Published in:
- British Journal of Dermatology, 2015, v. 172, n. 5, p. 1371, doi. 10.1111/bjd.13469
- By:
- Publication type:
- Article
Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
- Published in:
- British Journal of Dermatology, 2014, v. 170, n. 2, p. 398, doi. 10.1111/bjd.12632
- By:
- Publication type:
- Article
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
- Published in:
- British Journal of Dermatology, 2013, v. 168, n. 4, p. 844, doi. 10.1111/bjd.12214
- By:
- Publication type:
- Article
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
- Published in:
- British Journal of Dermatology, 2012, v. 167, n. 5, p. 1145, doi. 10.1111/j.1365-2133.2012.11142.x
- By:
- Publication type:
- Article
Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 11, p. 1940, doi. 10.1111/jdv.15012
- By:
- Publication type:
- Article
Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2018, v. 32, n. 9, p. 1515, doi. 10.1111/jdv.14910
- By:
- Publication type:
- Article
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2013, v. 27, n. 12, p. 1535, doi. 10.1111/jdv.12046
- By:
- Publication type:
- Article